Literature DB >> 6549746

Comparative evaluation of the therapeutic efficacy of a pH-sensitive enteric coated pancreatic enzyme preparation with conventional pancreatic enzyme therapy in the treatment of exocrine pancreatic insufficiency.

S K Dutta, J Rubin, J Harvey.   

Abstract

The therapeutic efficacy of a pH-sensitive enteric coated pancreatic enzyme preparation was compared with conventional pancreatic enzyme preparations in 6 adult patients with exocrine pancreatic insufficiency. Fecal fat excretion and postprandial duodenal recovery of orally ingested pancreatic enzymes were evaluated after ingestion of each preparation. Fecal fat excretion decreased significantly (p less than 0.005) on treatment with pH-sensitive and conventional pancreatic enzyme preparations. Postprandial concentration and delivery of trypsin and lipase in samples aspirated from duodenojejunal junction were higher after ingestion of conventional pancreatic enzyme preparation as compared to the pH-sensitive enteric coated preparation. The difference, however, did not reach statistical significance. Our observations suggest that the pH-sensitive enteric coated pancreatic enzyme preparation is only as effective as conventional pancreatic enzyme preparations in controlling fat malabsorption in patients with exocrine pancreatic insufficiency. Failure of pH-sensitive enteric coated preparation to deliver greater quantities of pancreatic enzymes at duodenojejunal junction is most likely related to the impaired release of enzymes from microspheres due to low intraluminal pH in the upper small intestine in pancreatic insufficiency.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6549746

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

Review 1.  Pancreatic enzyme replacement therapy.

Authors:  P Layer; J Keller; P G Lankisch
Journal:  Curr Gastroenterol Rep       Date:  2001-04

2.  Monitoring enzyme replacement treatment in exocrine pancreatic insufficiency using the cholesteryl octanoate breath test.

Authors:  S Mundlos; P Kühnelt; G Adler
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

3.  Advocating for patients through clinical research.

Authors:  Leslie Hendeles
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

4.  Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.

Authors:  Gavin R Graff; John McNamara; James Royall; Steven Caras; Kristin Forssmann
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

5.  Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis.

Authors:  S K Dutta; V S Hubbard; M Appler
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

Review 6.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

Review 7.  Pancreatic enzymes in chronic pancreatitis.

Authors:  P Layer; G Holtmann
Journal:  Int J Pancreatol       Date:  1994-02

8.  Comparison of four pancreatic extracts in cystic fibrosis.

Authors:  D W Beverley; J Kelleher; A MacDonald; J M Littlewood; T Robinson; M P Walters
Journal:  Arch Dis Child       Date:  1987-06       Impact factor: 3.791

9.  Use of pancreatic Schilling test to determine efficiency of pancreatic enzyme delivery in pancreatic insufficiency.

Authors:  W R Brugge; H J Goldberg; C A Burke; B J Depping
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

10.  Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.

Authors:  Devi Mukkai Krishnamurty; Atoosa Rabiee; Sanjay B Jagannath; Dana K Andersen
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.